Table 1.
Demographic and clinical data of patients with SCZ. Data are presented as a number (percentage) or median (Q1; Q3).
| Men | Women | ||
|---|---|---|---|
| Age (Years) | 40 (33; 47) | 41 (35; 50) | |
| U = 5231.00; p = 0.150 | |||
| Age when first diagnosed (years) | 23 (18; 29) | 25 (19; 29) | |
| U = 5103.50; p = 0.263 | |||
| Smoking | No | 56 (44.4%) | 37 (50.0%) |
| Yes | 70 (55.6%) | 37 (50.0%) | |
| χ2 = 0.58; p = 0.447 | |||
| History of alcohol abuse | No | 107 (84.9%) | 68 (91.9%) |
| Yes | 19 (15.1%) | 6 (8.1%) | |
| χ2 = 2.07; p = 0.150 | |||
| History of drug abuse | No | 84 (66.7%) | 63 (85.1%) |
| Yes | 42 (33.3%) | 11 (14.9%) | |
| χ2 = 8.16; p = 0.004 | |||
| Antipsychotic dose (mg/day) * | 600 (375; 980) | 625 (375; 950) | |
| U = 4694.00; p = 0.935 | |||
| BNSS score | 29 (22; 36) | 29 (21; 39) | |
| U = 4601.00; p = 0.877 | |||
| BNSSanh | 6 (4; 9) | 7 (5; 10) | |
| U = 5120.50; p = 0.243 | |||
| BNSSasoc | 4 (3; 5) | 4 (2; 4) | |
| U = 4122.50; p = 0.158 | |||
| BNSSavol | 6 (4; 8) | 6 (3; 8) | |
| U = 4660.50; p = 0.997 | |||
| BNSSalog | 2 (1; 4) | 2 (0; 4) | |
| U = 4401.50; p = 0.502 | |||
| BNSSblaf | 8 (6; 11) | 9 (7; 12) | |
| U = 5122.00; p = 0.243 | |||
| CAINS score | 23 (17; 27) | 22 (16; 28) | |
| U = 4653.00; p = 0.982 | |||
| CAINSsoc | 6 (4; 8) | 6 (4; 7) | |
| U = 4281.00; p = 0.332 | |||
| CAINSvoc | 2 (0; 6) | 2 (0; 5) | |
| U = 4665.50; p = 0.993 | |||
| CAINSrec | 4 (3; 6) | 4 (3; 6) | |
| U = 4997.00; p = 0.389 | |||
| CAINSexp | 7 (5; 9) | 7 (5; 9) | |
| U = 4816.00; p = 0.695 | |||
| CDSS score | 2 (0; 4) | 3 (1; 7) | |
| U = 5459.00; p = 0.040 | |||
| GAF score | 50 (41; 61) | 45 (40; 61) | |
| U = 4073.00; p = 0.135 | |||
| PANSS score | 69 (62; 79) | 69 (61; 83) | |
| U = 4930.00; p = 0.498 | |||
| PANSSpos | 12 (11; 16) | 13 (11; 16) | |
| U = 4830.50; p = 0.669 | |||
| PANSSneg | 21 (18; 23) | 20 (17; 25) | |
| U = 4621.50; p = 0.918 | |||
| PANSSgen | 35 (31; 40) | 36 (31; 44) | |
| U = 5084.50; p = 0.284 | |||
| RPAS score | 18 (13; 23) | 16 (10; 21) | |
| U = 3909.00; p = 0.057 | |||
| Physical anhedonia | No | 104 (82.5%) | 49 (66.2%) |
| Yes | 22 (17.5%) | 25 (33.8%) | |
| χ2 = 6.61; p = 0.009 | |||
| RSAS score | 12 (8; 16) | 13 (7; 17) | |
| U = 4787.00; p = 0.751 | |||
| Social anhedonia | No | 108 (85.7%) | 51 (68.9%) |
| Yes | 18 (14.3%) | 23 (31.1%) | |
| χ2 = 8.07; p = 0.005 | |||
* in chlorpromazine equivalents; BNSS-The Brief Negative Symptom Scale; CAINS-Clinical Assessment Interview for Negative Symptoms; CDSS-The Calgary Depression Scale for SCZ; GAF-Global Assessment of Functioning; PANSS-Positive and Negative Syndrome Scale; RPAS-Revised Physical Anhedonia Scale; RSAS-Revised Social Anhedonia Scale; significant results are indicated in bold.